Clinical trials: Hematopoietic Malignancy
Hematologic Neoplasms, Relapse
Amplifying Graft-Versus-Tumor Effect by Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion
The investigators have previously shown that depletion of CD4+CD25+FoxP3+ regulatory T cells (Treg) enhances the alloreactivity of T lymphocytes, as attested by an accelerated GVHD after allogeneic hematopoietic stem cell…
- Trial name
- ILD-Treg (NCT00987987)
- Testing
- donor lymphocyte infusion
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Relapse Leukemia, Refractory Acute Myeloid Leukemia
Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML
The primary objective of this study was to evaluate the efficacy of MTBF conditioning regimen of salvageable allo-HSCT in patients with relapsed or refractory acute myeloid leukemia.
- Conditions
- Relapse Leukemia, Refractory Acute Myeloid Leukemia, Conditioning, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT06385808
- Testing
- MTBF regimen
- Volunteers
- 37 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Hematopoietic Stem Cell Transplantation (HSCT)
Prehabilitation to Improve Frailty, Function, and Quality of Life in Candidates for Hematopoietic Stem Cell Transplantation
Candidates for hematopoietic stem cell transplantation (HSCT) frequently experience declines in strength, physical function, and quality of life before the procedure.
- Trial name
- PREHAB-HSCT (NCT07255521)
- Testing
- Multimodal Prehabilitation
- Where
- 2 sites in Chile
- Volunteers
- 68 people
- Sponsor
- Hospital del Salvador
Non-hodgkin's Lymphoma, Mantle Cell Lymphoma
VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma
This is a Phase I/II trial designed to study the toxicity and Maximum Tolerated Dose (MTD) of bortezomib in combination with BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan) and autologous hematopoietic stem cell…
- Trial name
- NCT00571493
- Testing
- Bortezomib, BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Nebraska
Leukemia, Lymphoma
A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers
Hematopoietic cell transplantation (BMT), or commonly referred to as blood and marrow transplantation (BMT), is a potentially life-saving therapy for many malignant and non-malignant conditions.
- Conditions
- Leukemia, Lymphoma, Brain Tumor
- Trial name
- NCT02409121
- Testing
- Education information system
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Childhood Cancer
Cardiopulmonary Fitness and Its Clinical Determinants of a Population of Childhood Cancer Survivor
Medical progress have made it possible to considerably improve the survival of children with an oncological disease. Currently, the survival rate increased to above 90 % in the most developed countries .
- Trial name
- ONCO-SPORT (NCT04815447)
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Montpellier
Multiple Myeloma, Non-Hodgkins Lymphoma
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
The purpose of this study is to determine whether it is safe and effective to collect peripheral blood hematopoietic stem cells 16 hours rather than the usual 11 hours after administration of plerixafor.
- Trial name
- NCT01042717
- Testing
- Plerixafor
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Shi, Patricia, M.D.
Leukemia, MDS
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
The purpose of this study is to determine whether stem cells collected from a donor's blood stream will be as safe and effective as using bone marrow collected from a donor's pelvic bone.
- Conditions
- Leukemia, MDS, Myelofibrosis, Lymphoma
- Trial name
- NCT02167958
- Testing
- Fludarabine, Cyclophosphamide, Mesna
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Rafic Farah, MD
Lymphoma, Non-Hodgkin, Blood and Marrow Transplant (BMT)
90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL
To test a new way to approach hematopoietic stem cell transplantation for Relapsed or Resistant Non-Hodgkin's Lymphoma.
- Trial name
- NCT00186589
- Testing
- 90Y Ibritumomab tiuxetan
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Acute Myeloid Leukemia, Leukemia
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute myeloid leukemia (AML)…
- Conditions
- Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes
- Trial name
- NCT06138587
- Testing
- Cytokine Induced Memory-like Natural Killer Cells, Interleukin-2
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
This phase II trials studies the effects of yttrium-90 labeled anti-CD25 monoclonal antibody combined with BEAM chemotherapy conditioning in treating patients with Hodgkin lymphoma that does not response to treatment (refractory)…
- Trial name
- NCT04871607
- Testing
- Basiliximab, Carmustine, Cytarabine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
Patients with acute leukemia relapsing after allotransplant and who respond to anti-leukaemia interventions are at high-risk of a second relapse.
- Conditions
- Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation, Acute Leukemia, Minimal Residual Disease
- Trial name
- NCT03297528
- Testing
- donor lymphocyte infusion
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and…
- Conditions
- Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Trial name
- NCT02822495
- Testing
- tabelecleucel
- Sponsor
- Atara Biotherapeutics
Leukemia
Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation
Efficacy study about donor derived CD19-target T cell to treat B-ALL post hematopoietic stem cell transplantation
- Trial name
- NCT04336501
- Testing
- IM19 CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Hematopoietic and Lymphoid Cell Neoplasm
Fecal Microbiota Transplantation for Steroid Resistant/Dependent Acute GI GVHD
The purpose of this study is to evaluate the efficacy and safety of fecal microbiome transplantation in patients with steroid resistant/dependent acute gastrointestinal graft-versus-host disease (GVHD).
- Trial name
- FEMITGIGVHD (NCT03812705)
- Testing
- fecal microbiome transplantation
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Hematologic Cancer
Non-Pharmacological Interventions for Neurotoxicity in Hematologic Patients Receiving CAR-T Therapy
The goal of this clinical trial is to learn if two non-pharmacological strategies can help reduce neurotoxicity caused by CAR-T cell therapy in adult patients with hematologic cancer, both sexes, aged 18 to 80 years.
- Trial name
- CARE-T (NCT07173166)
- Testing
- Physical activity, Physical activity and nutrition
- Where
- 2 sites in Spain
- Volunteers
- 338 people
- Sponsor
- Instituto de Investigacion Sanitaria INCLIVA
Precursor Lymphoid Neoplasms
Personalized Therapy of Precursor Lymphoid Neoplasms
The primary goal of this study by The Polish Adult Leukemia Group (PALG) is to verify if individual therapeutic approach taking into account biological and phenotypic differences as well as response at the level of minimal…
- Trial name
- NCT01665001
- Testing
- Treatment strategy: induction, consolidation, HSCT, maintenance
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice
Graft Versus Host Disease, Graft Vs Host Disease
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an effective GVHD prevention approach for people with blood cancer who have…
- Conditions
- Graft Versus Host Disease, Graft Vs Host Disease, Hematologic Malignancy
- Trial name
- NCT07006506
- Testing
- Belumosudil
- Where
- 8 sites in United States
- Volunteers
- 46 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Hodgkin's Lymphoma
Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgkin's Lymphoma
A study to determine the accuracy of FLT-PET in quantifying tumor cell proliferation at the initial staging of patients with Non-Hodgkin's Lymphoma in comparison wit the "gold standard" FDG-PET.
- Trial name
- NCT00775957
- Testing
- FLT-PET scan, FDG-PET scan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Oklahoma
Myeloid Diseases
T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia
The main purpose of this study is to learn if a new combination of chemotherapy, in combination with low-dose radiation, will be safe for the patient, and at the same time provide the best opportunity to cure the bone marrow…
- Trial name
- NCT03531736
- Testing
- Antithymocyte globulin (Rabbit), fludarabine, total body irradiation
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.